Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 17 de 17
Filter
1.
G Chir ; 40(1): 70-74, 2019.
Article in English | MEDLINE | ID: mdl-30771803

ABSTRACT

AIM: We report a case of squamous carcinoma arising from a pilonidal sinus. CASE REPORT: Patient of 83 years old, that after 30 years had a recurrence of pilonidal sinus revealed by a sacral abscess studied with pelvic CT scan and MRI. After clinical investigation, traditional open surgical technique was performed and pathologic studies revealed a squamous carcinoma. The patient performed a new CT scan with persistence of disease, and a second surgical look with mass excision until the presacral fascia and V-Y flap was performed. Histological exami-nation was found to be positive for squamous carcinoma on the margin and the patient underwent adjuvant radiotherapy cycles with a close follow-up with evidence of free disease survival. He died after 5 years for old age. DISCUSSION: The incidence of carcinoma arising from a pilonidalis sinus is about 0.1% and the most important risk factor is represented by a chronic abscess from 20-30 years. In literature there are about 100 cases. Gold standard treatment is surgery with complete excision of the presacral fascia, while radiotherapy decrease the risk of recurrence. CONCLUSION: All cases reported in literature are submitted as case report. Sacro-coccyxal fistula should be treated early because chronic inflammation can determine neoplastic degeneration. Histological examination should be performed routinely. Gold standard is surgery with wide excision. There is no evidence about the gold standard for the reconstructive time.


Subject(s)
Carcinoma, Squamous Cell/complications , Pilonidal Sinus/complications , Skin Neoplasms/complications , Aged, 80 and over , Carcinoma, Squamous Cell/pathology , Carcinoma, Squamous Cell/therapy , Fatal Outcome , Humans , Magnetic Resonance Imaging , Male , Pilonidal Sinus/pathology , Pilonidal Sinus/surgery , Second-Look Surgery , Skin Neoplasms/pathology , Skin Neoplasms/therapy , Tomography, X-Ray Computed
2.
G Chir ; 39(6): 399-402, 2018.
Article in English | MEDLINE | ID: mdl-30563607

ABSTRACT

The rate of pancreaticoduodenectomy (PD) performed for both benign and malignant periampullary diseases has increased. In addition, Roux-en-Y reconstruction after distal gastrectomy for cancer or ulcer is still widely used. Therefore, a surgeon may be confronted with a partially- gastrectomized patient who needs a PD. This is a very challenging circumstance for surgeons because of adhesions, bloodstream, anatomical changes and length of the remnant intestine. In our experience, we performed two pancreaticoduodenectomies after distal gastrectomy in patients with periampullary tumors. We preserve gastrojejunal anastomosis and perform an end-to-side pancreaticojejunostomy (PJ) on the afferent limb of gastrojejunal anastomosis and a termino-lateral hepaticojejunal anastomosis on an independent transmesocolic Roux-en-Y limb. In literature, few cases of PD after distal gastrectomy are reported and most of them consider only PD after Billroth II reconstruction. Many authors have demonstrated pancreaticogastrostomy (PG) is superior to PJ in terms of lower risk of pancreatic and biliary fistula, but it is not possible to anastomose pancreas stump with gastric wall in patients who have been undergone distal gastrectomy. For this reason, we retrospectively review our experience about PD following distal gastrectomy and suggest a novel standardized technique which allow surgeons to benefit from same advantages of a typical PG also in this group of patients.


Subject(s)
Anastomosis, Roux-en-Y , Gastrectomy/methods , Pancreaticoduodenectomy/methods , Plastic Surgery Procedures/methods , Adenocarcinoma/surgery , Aged , Carcinoma, Signet Ring Cell/drug therapy , Carcinoma, Signet Ring Cell/pathology , Carcinoma, Signet Ring Cell/surgery , Chemotherapy, Adjuvant , Cholecystectomy , Combined Modality Therapy , Duodenum/pathology , Duodenum/surgery , Female , Humans , Intestine, Small/surgery , Liver/surgery , Lymphoma, Non-Hodgkin/surgery , Male , Neoplasm Invasiveness , Neoplasms, Second Primary/surgery , Pancreatic Ducts/surgery , Pancreatic Neoplasms/surgery , Pancreaticojejunostomy , Stents , Stomach Neoplasms/surgery
3.
G Chir ; 39(6): 383-387, 2018.
Article in English | MEDLINE | ID: mdl-30563603

ABSTRACT

AIM: Complication of Crohn's disease (CD) of the small intestine is small bowel adenocarcinoma (SBA). A lot of studies on Crohn's disease have estimated the increased relative risk of small bowel carcinoma compared to the general population. In clinical settings, it is difficult to detect SBA in CD, therefore most of cases are diagnosed after surgery for strictures without suspicion of malignancy. CASE REPORT: The present case concerns a 48-year-old man with a suspicious 5-year history of untreated chronic inflammatory bowel disease. The patient was admitted to our unit with persistent abdominal pain, 20 kg weight loss and intestinal obstruction, confirmed at CT scans. It was performed an emergency laparotomy, terminal ileus was resected and intestinal continuity was restored. Histological examination revealed a poorly differentiated adenocarcinoma. DISCUSSION: The risk factors of SBA include long-standing and extensive Crohn's disease, young age, male sex, smoke, early onset, complications such as strictures and fistulas The most common clinical presentation of small bowel carcinoma in Crohn's disease is intestinal obstruction accompanied by wheight loss. The diagnosis is very difficult because imaging techniques may not be able to differentiate areas of small bowel carcinomas from benign fibrotic or acute inflammatory strictures. CONCLUSION: Small bowel adenocarcinoma is a rare disease but this evenience must be considered in patients with strictures for Crohn's disease. Preoperative diagnosis is still highly challenging despite significant radiological and endoscopic progress.


Subject(s)
Adenocarcinoma/etiology , Crohn Disease/complications , Ileal Neoplasms/etiology , Adenocarcinoma/secondary , Adenocarcinoma/surgery , Antirheumatic Agents/adverse effects , Antirheumatic Agents/therapeutic use , Crohn Disease/drug therapy , Humans , Ileal Neoplasms/surgery , Immunocompromised Host , Immunosuppressive Agents/therapeutic use , Infliximab/adverse effects , Infliximab/therapeutic use , Lymphatic Metastasis , Male , Malnutrition/etiology , Malnutrition/therapy , Middle Aged , Parenteral Nutrition, Total , Smoking/adverse effects , Time-to-Treatment , Tumor Necrosis Factor-alpha/antagonists & inhibitors
4.
G Chir ; 38(5): 213-218, 2017.
Article in English | MEDLINE | ID: mdl-29280699

ABSTRACT

AIM: The aim of our study is to focus on hTERT (human Telomerase Reverse Transcriptase) expression to identify tumoral tissue after a comparison to TP53 and KRAS. More than 85% of cancer cells contain genetic aberrations and also overexpression of hTERT, and, in fact, the promoter of hTERT characterizes all malignant cells. PATIENTS AND METHODS: Our sample is composed of 18 patients, including 10 with CRC that underwent surgical procedure and 8 patients without CRC, which represent the control group. The hTERT gene expression, KRAS and p53 were evaluated by methodical Real Time - PCR on RNA extracted from tumor tissues, peritumoral tissue and control cases. RESULTS: Within the CRC group the evaluation of the tumor tissue showed an increase of hTERT expression with a statistical significance (> 0.1) in 5 of these, also associated with substantial increase of KRAS (> 0.2). The peritumoral tissue assessment showed important increase in KRAS in 4 patients (> 0.2), while hTERT is not found to be particularly increased. The value of p53 did not show any particular significance (<0.1). DISCUSSION: The analysis of our data leads us to consider that the increase of hTERT is evident in patients suffering from CRC and that some of them will become significant in relation to the increase of KRAS and independent of p53. In peritumoral tissues, however, KRAS increases considerably, instead hTERT maintains a low concentration and this is compatible with the cellular evolution of the neoplastic tissue adjacent to the tumor. CONCLUSIONS: hTERT could be used for diagnosis and prognosis in the future, to be able to identify the risk of tumor progression and to set up an adequate therapy.


Subject(s)
Colorectal Neoplasms/enzymology , Telomerase/physiology , Aged , Colorectal Neoplasms/metabolism , Female , Humans , Male , Middle Aged , Retrospective Studies , Telomerase/biosynthesis
5.
G Chir ; 38(5): 229-232, 2017.
Article in English | MEDLINE | ID: mdl-29280702

ABSTRACT

The giant condyloma acuminatum or Buschke-Loewenstein tumor is a rare, sexually transmitted disease. It is an epithelial tumor characterized by its high potential of malignancy towards developing into a highly invasive squamous cell carcinoma. The present case concerns a drug addicted 40-year-old man who smuggled drugs using his rectum. He had a partially ulcerated mass in the perianal area of about 20 x 10 cm. He reported a progressive growth of this neoplasm during the last 3 years associated with perianal pain, obstructed defecation, bad sitting posture, no fever and weight loss. Our first approach was a left laparoscopic loop colostomy for a fecal diversion and antalgic purpose, and biopsy of the perineal mass. Then, he underwent a complete excision of the perianal neoplasm. The pathologist's positive diagnosis of a well differentiated squamous cell carcinoma, evidently necessitated the radicalization of the surgical procedure of abdominal perineal resection. In consideration of the surgical wound depth and size, a VAC Therapy with Negative Pressure Wound Therapy was applied. The BLT incidence rate has been steadily increasing over the last decade especially among male patients. An aggressive surgical approach is usually to get the best oncologic outcome but the difficult management of the perianal wound is challenging. In our experience VAC therapy has been shown to be an effective tool in promoting the healing of the perineal wound after abdominoperineal resection.


Subject(s)
Buschke-Lowenstein Tumor/surgery , Proctectomy , Rectal Neoplasms/surgery , Adult , Humans , Male , Treatment Outcome
6.
G Chir ; 38(4): 202-204, 2017.
Article in English | MEDLINE | ID: mdl-29182903

ABSTRACT

INTRODUCTION: Splenic cysts are benign tumors, accidentally detected using US or CT scan. They are classified into true cyst (primary, 25%) and pseudocyst (secondary, 75%). Conventional treatment of splenic cyst, especially giant, symptomatic and complicated has been open or laparoscopic total splenectomy. Recently, partial splenectomy is recommended as well to preserve its hematopoietic function and homeostasis of blood, but it is not considered safe for complications as intra and post operative bleeding. CASE REPORT: A 46 years old man, martial arts practitioner, underwent US abdomen scan because of left upper quadrant pain, with evidence of a splenic mass. He underwent also CT and MRI, which revealed "oval giant splenic mass of 12 cm diameter located in superior splenic pole that can be firstly referred to cyst". Considered patient's frequency to thoraco-abdominal traumas, we decided to perform a total laparoscopic splenectomy. Surgical treatment was performed with a three trocar technique and lasted 150 minutes. Post-operative follow-up was regular and abdominal drain was removed in 4th POD (Post Operative Day). Patient was discharged in 5th POD. Pathological examination revealed epidermoid cyst. CONCLUSIONS: Total splenectomy needs to be performed in cases of giant cyst and in our limited experience it is a safe approach.


Subject(s)
Epidermal Cyst/surgery , Laparoscopy , Splenectomy/methods , Splenic Diseases/surgery , Epidermal Cyst/pathology , Humans , Male , Middle Aged , Splenic Diseases/pathology
7.
G Chir ; 38(1): 23-26, 2017.
Article in English | MEDLINE | ID: mdl-28460199

ABSTRACT

AIM: The aim of our study is to compare the outcomes of laparoscopic resection (LR) and open resection (OR) for colorectal cancer surgery evaluating lymph node assessment. It may be important to remove and examine an adequate number of lymph nodes because a more extensive nodal resection has been associated to higher survival rate and lower recurrences. PATIENTS AND METHODS: 150 patients (74 females and 76 males) with colorectal cancer were enrolled and analyzed from January 2006 to March 2010 in our Unit. 100 procedures were performed with traditional laparotomy and 50 procedures laparoscopically. A strict follow-up was scheduled every 1-3-6 months after surgery and, therefore, every year. RESULTS: Laparoscopic techniques require a longer operating time. 2484 total lymph nodes examined with a mean of 16,56 removed per resection in all procedures. 1632 lymph nodes were removed during open procedures and 852 removed during laparoscopy. The scheduled follow-up demonstrated that local recurrence and distant metastasis presented with no significant differences between two groups and overall survival and disease-free survival were assessed over 5 year in 80% of patients. CONCLUSIONS: According to our experience, laparoscopic colorectal surgery is safe and feasible, with better short-term outcomes and oncological adequacy comparable to open approach.


Subject(s)
Colorectal Neoplasms/pathology , Colorectal Neoplasms/surgery , Laparoscopy , Lymph Nodes/pathology , Adult , Aged , Aged, 80 and over , Digestive System Surgical Procedures/methods , Female , Humans , Intraoperative Period , Laparoscopy/methods , Lymphatic Metastasis/pathology , Male , Middle Aged , Retrospective Studies , Treatment Outcome
8.
G Chir ; 38(6): 299-302, 2017.
Article in English | MEDLINE | ID: mdl-29442062

ABSTRACT

INTRODUCTION: Gallstone ileus is an uncommon condition of mechanical bowel obstruction caused by the passage of a gallstone into the bowel. It occurs more frequently in female patients older than 65 years and often for a biliary-enteric fistula. The pathognomonic features of gallstone ileus - the Rigler's triad - are pneumobilia, ectopic gallstone and bowel obstruction. Less commonly, a gallstone may enter the intestinal lumen through the common bile duct, after endoscopic retrograde cholangiopancreatography, and very rarely in colecistectomized patient. CASE REPORT: A 92-year old colecistectomized male patient was admitted to our unit for the clinical suspicion of bowel obstruction. He was also submitted to ERCP seven months before. Physical examination revealed tenderness in the lower abdomen and CT showed intrahepatic and extrahepatic biliary dilatation and small bowel obstruction with a hyperdense formation in right iliac fossa as gallstone ileus. It was performed an emergency laparotomy with enterotomy and a 5x3 cm gallstone removal. There were no post-operative complications and the patient was discharged 8 days after surgery. DISCUSSION: Cholecysto-duodenal fistulas are most frequently described in worldwide-reports. There are only few cases in literature of gallstone which enter the gastrointestinal tract following endoscopic retrograde cholangiopancreatography (ERCP) and sphincterotomy through papilla of Vater, without a biliary-enteric fistula, causing gallstone ileus. If the patient is cholecistectomized, gallstone removal alone is required. CONCLUSION: The differential diagnosis in case of small bowel obstruction should always include gallstone ileus, even if the patient previously underwent a cholecystectomy.


Subject(s)
Cholangiopancreatography, Endoscopic Retrograde/adverse effects , Cholecystectomy , Gallstones/etiology , Ileus/etiology , Postoperative Complications/etiology , Sphincterotomy, Endoscopic/adverse effects , Aged, 80 and over , Humans , Male
9.
Transplantation ; 76(11): 1632-7, 2003 Dec 15.
Article in English | MEDLINE | ID: mdl-14702539

ABSTRACT

BACKGROUND: Invasive fungal infections (IFI), particularly those caused by Aspergillus and other angioinvasive molds, are associated with an excessive mortality despite therapy. METHODS: Voriconazole was prescribed on a compassionate basis to patients with IFI who were intolerant to or who had progressed despite standard therapy. Outcome was determined by protocol-based criteria as established by the consensus definitions (complete response [CR], partial response [PR], stable disease, failure, and intolerance). RESULTS: Forty-five patients were enrolled in a compassionate release program (29 [64%] because of failure of response to standard therapy), between 1998 and 2002. Of the 45 patients enrolled, 35 (78%) had invasive Aspergillus, 3 (7%) had Fusarium, and 2 (4%) had Scedosporium infections. Underlying illnesses were as follows: 13 (29%) solid-organ transplant (SOT), 11 (24%) BMT, and 7 (13%) hematologic malignancy. Site of infection was as follows: 26 (58%) pulmonary, 9 (20%) disseminated, 5 (11%) central nervous system (CNS), and 3 (7%) sinus. Overall response rates were as follows: 9 (20%) CR, 17 (38%) PR, 15 (33%) failure, and 4 (9%) intolerant. Seven of the eight (88%) patients with sinus or CNS disease demonstrated stabilization of the IFI. The median duration of voriconazole therapy was 79 days with 9 (20%) patients receiving over 1 year of therapy. Nine thousand one hundred twenty-eight days of therapy were given with only four serious adverse events in two cases considered possibly or probably drug related. CONCLUSIONS: In this population of severely immunocompromised patients with life-threatening IFI who have failed or were intolerant to standard antifungal therapy, voriconazole demonstrated substantial efficacy and an acceptable level of toxicity.


Subject(s)
Antifungal Agents/therapeutic use , Mycoses/drug therapy , Pyrimidines/therapeutic use , Salvage Therapy/methods , Triazoles/therapeutic use , Adult , Aged , Antifungal Agents/adverse effects , Aspergillosis/drug therapy , Bone Marrow Transplantation/adverse effects , Child , Drug Resistance, Fungal , Female , Hematologic Neoplasms/complications , Humans , Immunocompromised Host , Middle Aged , Mycoses/etiology , Neoplasms/complications , Transplantation/adverse effects , Treatment Failure , Voriconazole
10.
Epidemiol Infect ; 128(3): 391-6, 2002 Jun.
Article in English | MEDLINE | ID: mdl-12113482

ABSTRACT

Streptococcus pyogenes (group A streptococcus) strains may express several distinct fibronectin-binding proteins (FBPs) which are considered as major streptococcal adhesins. Of the FBPs, SfbI was shown in vitro to promote internalization of the bacterium into host cells and has been implicated in persistence. In the tropical Northern Territory, where group 4 streptococcal infection is common, multiple genotypes of the organism were found among isolates from invasive disease cases and no dominant strains were observed. To determine whether any FBPs is associated with invasive disease propensity of S. pyogenes, we have screened streptococcal isolates from bacteraemic and necrotizing fasciitis patients and isolates from uncomplicated infections for genetic endowment of 4 FBPs. No difference was observed in the distribution of sfbII, fbp54 and sfbI between the blood isolates and isolates from uncomplicated infection. We conclude that the presence of sfbI does not appear to promote invasive diseases, despite its association with persistence. We also show a higher proportion of group A streptococcus strains isolated from invasive disease cases possess prtFII when compared to strains isolated from non-invasive disease cases. We suggest that S. pyogenes may recruit different FBPs for different purposes.


Subject(s)
Adhesins, Bacterial , Bacterial Proteins/genetics , Carrier Proteins/genetics , Disease Outbreaks , Streptococcal Infections/pathology , Streptococcus pyogenes/genetics , Streptococcus pyogenes/pathogenicity , Australia/epidemiology , Bacterial Proteins/pharmacology , Carrier Proteins/pharmacology , Humans , Polymerase Chain Reaction , Streptococcus pyogenes/isolation & purification , Tropical Climate
11.
Cutis ; 67(2): 145-8, 2001 Feb.
Article in English | MEDLINE | ID: mdl-11236225

ABSTRACT

Allergic granulomatosis angiitis (AGA) is a rare systemic vasculitis of unknown etiology. Most patients are adults in their third to fourth decade of life. The combination of asthma, eosinophilia, and necrotizing vasculitis is almost invariably present. Cutaneous lesions are found in up to 70% of the patients and include nodules, hemorrhagic lesions, and erythema multiformelike lesions. We provide a case report of a 30-year-old woman with asthma who presented with acral purpuric plaques and was diagnosed with AGA.


Subject(s)
Asthma/complications , Churg-Strauss Syndrome/complications , Churg-Strauss Syndrome/diagnosis , Adult , Anti-Inflammatory Agents/therapeutic use , Asthma/drug therapy , Churg-Strauss Syndrome/drug therapy , Cimetidine/therapeutic use , Diagnosis, Differential , Female , Histamine H2 Antagonists/therapeutic use , Humans , Prednisone/therapeutic use
13.
Psychosomatics ; 36(6): 561-3, 1995.
Article in English | MEDLINE | ID: mdl-7501787

ABSTRACT

Although cytomegalovirus (CMV) is rarely cultured from peripheral-blood leukocytes of immunocompetent patients, it may be cultured from up to 60% of renal transplant recipients, 1 to 4 months after transplantation. During this same period, renal transplant recipients are often referred for psychiatric evaluation. Since CMV may infect the central nervous system, the relationship between isolation of CMV from peripheral-blood leukocytes (viremia) and psychiatric evaluation was investigated in 80 renal allograft recipients at the Massachusetts General Hospital. Five of 16 (31%) patients with viremia and 7 of 64 (11%) patients without viremia required psychiatric consultation (P = 0.04, two-tailed Fisher exact test). CMV viremia may be an important but treatable contributor to psychiatric symptoms in the transplant recipient.


Subject(s)
Cytomegalovirus Infections/psychology , Kidney Transplantation/psychology , Neurocognitive Disorders/psychology , Opportunistic Infections/psychology , Viremia/psychology , Cytomegalovirus/isolation & purification , Cytomegalovirus Infections/diagnosis , Diagnosis, Differential , Humans , Leukocytes/virology , Neurocognitive Disorders/diagnosis , Opportunistic Infections/diagnosis , Patient Care Team , Postoperative Complications/diagnosis , Postoperative Complications/psychology , Prospective Studies , Retrospective Studies , Viremia/diagnosis
14.
Online J Curr Clin Trials ; Doc No 15: [4083 words; 46 paragraphs], 1992 Aug 11.
Article in English | MEDLINE | ID: mdl-1343609

ABSTRACT

BACKGROUND: Prophylaxis with low-dose trimethoprim-sulfamethoxazole has been shown to be cost-effective in the prevention of urinary tract infections, pyelonephritis, urosepsis, and pneumocystis pneumonia in renal transplant recipients. Ciprofloxacin, effective against almost all urinary tract pathogens in this patient population, represents a promising alternative prophylactic agent for patients unable to tolerate trimethoprim-sulfamethoxazole due to toxicity. METHODS: We conducted a randomized, double-blind trial to compare low-dose trimethoprim-sulfamethoxazole with ciprofloxacin for the prevention of urinary tract infections in renal transplant recipients. Patients received either ciprofloxacin (250 mg) or trimethoprim-sulfamethoxazole (80 mg trimethoprim, 400 mg sulfamethoxazole) daily for 6 months following transplantation. Treatment was considered successful if patients completed the 6-month course and 3-month follow-up period without evidence of urinary tract infection or drug-related toxicities. RESULTS: Of 103 eligible patients, 51 received ciprofloxacin and 52 received trimethoprim-sulfamethoxazole. At 6 months, treatment was successful in 75% (38 of 51) receiving ciprofloxacin and 71% (37 of 52) treated with trimethoprim-sulfamethoxazole (P = 0.87, relative risk 1.04, 95% confidence limits 0.83 to 1.33). Thirteen patients (25%) receiving trimethoprim-sulfamethoxazole withdrew from the study-4 for resistant urinary tract infection and 9 for drug-related toxicity, while 3 (6%) of the patients receiving ciprofloxacin withdrew because of drug-related toxicity (P = 0.016, relative risk of urinary tract infection or adverse event 0.24, 95% confidence limits 0.07 to 0.78). At 9 months, all 38 patients who completed the 6-month course of ciprofloxacin remained free of urinary tract infection, while an additional 4 patients who had received trimethoprim-sulfamethoxazole prophylaxis (total of 8 patients over the 9 months) developed urinary tract infections (P = 0.006, Fisher's exact test for urinary tract infection alone). Pneumocystis pneumonia occurred in a total of 7 (14%) patients who were randomized to ciprofloxacin, but 2 of the 7 had withdrawn from the study at least 2 weeks prior to the diagnosis of pneumocystis pneumonia. There were no cases of pneumocystis pneumonia in patients receiving trimethoprim-sulfamethoxazole (P = 0.006). Following completion of the study, monthly aerosolized pentamidine administered in conjunction with ciprofloxacin has provided complete protection against urinary tract infection and pneumocystis pneumonia in 30 transplant recipients unable to tolerate trimethoprim-sulfamethoxazole therapy. CONCLUSIONS: Ciprofloxacin is at least as effective as trimethoprim-sulfamethoxazole in the prevention of urinary tract infection in renal transplant recipients, and is better tolerated. Ciprofloxacin prophylaxis is associated with a higher incidence of pneumocystis pneumonia than is trimethoprim-sulfamethoxazole therapy. An uncontrolled follow-up study suggests that ciprofloxacin prophylaxis combined with monthly aerosolized pentamidine may be efficacious in preventing both urinary tract infection and pneumocystis pneumonia in renal transplant recipients.


Subject(s)
Ciprofloxacin/therapeutic use , Kidney Transplantation , Postoperative Complications/prevention & control , Trimethoprim, Sulfamethoxazole Drug Combination/therapeutic use , Urinary Tract Infections/prevention & control , Adult , Aerosols , Ciprofloxacin/adverse effects , Double-Blind Method , Drug Therapy, Combination , Female , Humans , Male , Middle Aged , Pentamidine/therapeutic use , Pneumonia, Pneumocystis/etiology , Pneumonia, Pneumocystis/prevention & control , Postoperative Complications/etiology , Treatment Outcome , Trimethoprim, Sulfamethoxazole Drug Combination/adverse effects , Urinary Tract Infections/etiology
15.
Transplantation ; 53(1): 68-72, 1992 Jan.
Article in English | MEDLINE | ID: mdl-1310173

ABSTRACT

A prospective study to investigate risk factors for CMV disease was conducted in 94 renal transplant recipients. CMV disease was defined as either unexplained fever for greater than 3 days with viremia or unexplained fever for greater than 3 days with isolation of CMV from the urine or throat wash and at least one of the following: leukopenia, elevated serum alanine aminotransferase, or biopsy-proved invasive tissue infection of the lung or gastrointestinal tract. Fifty-three patients received immunosuppressive regimens consisting of prednisone and cyclosporine, with or without azathioprine. The remaining 41 patients were treated with these agents plus OKT3 (21 received OKT3 to treat rejection, 20 received OKT3 prophylactically). Thirty-seven patients were at minimal risk of CMV disease (donor and recipient seronegative for CMV); 12 patients were at risk of primary disease (donor seropositive, recipient seronegative), and 45 were at risk of reactivation disease (recipient seropositive at the time of transplantation). The incidences of CMV disease in the 3 groups were 0%, 58%, and 36%, respectively. Although the incidence of CMV disease in patients at risk of primary disease was not influenced by the immunosuppressive regimen, immunosuppression had a profound effect on the occurrence of CMV disease in CMV-seropositive transplant recipients. The incidence of CMV disease in those receiving OKT3 was 59%; but only 21% in those who did not receive OKT3. OKT3 increased the risk of CMV disease five-fold (odds ratio 5.2 (95% confidence limits 1.4-17.5)). In the CMV-seropositive patient, OKT3 was also the most important predictor of CMV disease by multivariate analysis (P less than 0.002). A pilot study of preemptive therapy with ganciclovir (2.5 mg/kg daily during OKT3 therapy) in 17 patients decreased the incidence of CMV disease without appreciable toxicity.


Subject(s)
Antibodies, Viral/analysis , Cytomegalovirus Infections/etiology , Cytomegalovirus/immunology , Kidney Transplantation/adverse effects , Muromonab-CD3/therapeutic use , Adult , Cytomegalovirus Infections/prevention & control , Female , Humans , Male , Middle Aged , Risk
SELECTION OF CITATIONS
SEARCH DETAIL
...